This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer

With danuglipron, Pfizer could become a major player in the massive GLP-1 agonist market.If there's one thing healthcare giant Pfizer (PFE -0.12%) really needs right now, it's a compelling growth catalyst. This year, the company isn't expecting much in the way of growth and investors are unsure about how strong its long-term prospects are, which explains why the stock is in such a slump -- down more than 25% in three years.But sometimes all it takes is one successful product to turn a company's fortunes aro ...